Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis

Diabetologia

Volumn 56, Issue 5, 2013, Pages 973-984

  Hirst, J A ^a,b   Farmer, A J ^a,b   Dyar, A ^c   Lung, T W C ^d   Stevens, R J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Manchester   (United Kingdom)

^c TORBAY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical science; Human; Meta analysis; Oral pharmacological agents; Systematic review

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

ADD ON THERAPY; COCHRANE LIBRARY; DIABETES MELLITUS; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84876467856     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2856-6     Document Type: Review

References (56)

1. NICE (2008) CG66 type 2 diabetes: full guideline. In: NICE clinical guideline 66. www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf
2. Desai NR, Shrank WH, Fischer MA, et al.(2012) Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125(302):e301-e307
3. Ashcroft F (1996) Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 28:456-463
4. Nathan DM, Buse JB, Davidson MB, et al.(2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
5. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541-549
6. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC (2010) The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33:1859-1864
7. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389-394
8. Peters AL, Davidson MB (1991) Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 115:45-53
9. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ (1992) Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 15:953-959
10. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27:309-317
11. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT (1997) Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20:597-606
12. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
14. Higgins JPT, Green S (eds) (2005) Cochrane handbook for systematic reviews of interventions 4.2.4 [updated March 2005]. In: The Cochrane Library (Issue 2). Wiley, Chichester
15. Pasmantier R, Chaiken RL, Hirsch SR, Lebovitz HE (1990) Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM. Diabetes Care 13:42-46
16. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW (1998) Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21:1462-1469
17. British National Formulary (2010) BMJ Group and Pharmaceutical Press, London
18. Feinglos M, Dailey G, Cefalu W, et al.(2005) Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 68:167-175
19. Waugh N, Cummins E, Royle P, et al.(2010) Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Tech Assess 14:1-248
20. Melander A, Lebovitz HE, Faber OK (1990) Sulfonylureas. Why, which, and how? Diabetes Care 13(Suppl 3):18-25
21. Campbell IW (2010) Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract 64:791-801
22. Bland JM, Altman DG (1994) Statistics notes: some examples of regression towards the mean. BMJ 309:780
23. Camerini-Davalos RA, Bloodworth J, Velasco CA, Reddi AS (1994) Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients. Clin Ther 16:952-961
24. Fischer S, Patzak A, Reitzsch H, et al.(2003) Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metabol 5:38-44
25. Gallwitz B, Vaag A, Falahati A, Madsbad S (2010) Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 64:267-276
26. Zeller M, Danchin N, Simon D, et al.(2010) Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 95:4993-5002
27. Goldner MG, Knatterud GL, Prout TE (1971) Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 218:1400-1410
28. Adler AI, Stratton IM, Neil HA, et al.(2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419
29. Kahn SE, Haffner SM, Heise MA, et al.(2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
30. Banerji MA, Chaiken RL, Lebovitz HE (1995) Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44:466-470
31. Burant CF, Viswanathan P, Marcinak J, et al.(2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-1411
32. Damsgaard EM, Faber O, Froland A, Iversen S (1982) Fasting blood glucose, glycohaemoglobin and urinary glucose excretion in non-insulin-dependent patients with diabetes mellitus (NIDDM). Ugeskrift for Laeger 144:2342-2344 [article in Danish]
33. Ebeling P, Teppo AM, Koistinen HA, Koivisto VA (2001) Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metab Clin Exp 50:283-287
34. Goldberg RB, Holvey SM, Schneider J (1996) A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 19:849-856
35. Rosenstock J, Samols E, Muchmore DB, Schneider J (1996) Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19:1194-1199
36. Segal P, Feig PU, Schernthaner G, et al.(1997) The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20:687-691
37. Nauck M, Frid A, Hermansen K, et al.(2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
38. Jendle J, Nauck MA, Matthews DR, et al.(2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metabol 11:1163-1172
39. Goldman J, Tamayo RC, Whitehouse FW, Kahkonen DM (1984) Effect of glyburide on metabolic control and insulin binding in insulin-dependent diabetes mellitus. Diabetes Care 7:106-112
40. Gums JG, Curry J, de Oca GM, Skluth HA, Reynolds LR (1992) Treatment of type I diabetes with a combination of glyburide and insulin. Ann Pharmacother 26:757-762
41. Gutniak M, Karlander SG, Efendic S (1987) Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10:545-554
42. Karlander SG, Gutniak MK, Efendic S (1991) Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure. Diabetes Care 14:963-967
43. Kabadi UM, Birkenholz MR (1988) Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Arch Intern Med 148:1745-1749
44. Kabadi UM, McCoy S, Birkenholz M, Kabadi M (1995) More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Diab Med J Brit Diabet Assoc: 880-884
45. Leblanc H, Thote A, Chatellier G, Passa P (1990) Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics. Diabete et Metabolisme 16:93-97
46. Lewitt MS, Yu VK, Rennie GC, et al.(1989) Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 12:379-383
47. Lindstrom T, Nystrom FH, Olsson AG, Ottosson AM, Arnqvist HJ (1999) The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabet Med 16:820-826
48. Lins PE, Lundblad S, Persson-Trotzig E, Adamson U (1988) Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Acta Med Scand 223:171-179
49. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P (1992) Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 303:151-156
50. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G (1989) Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 12:623-629
51. Riddle MC, Schneider J (1998) Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 21:1052-1057
52. Schade DS, Mitchell WJ, Griego G (1987) Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. JAMA 257:2441-2445
53. Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L (1988) Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 31:206-213
54. Stuart CA, Gilkison CR, Carlson RF (1997) Effect of adding a sulfonylurea in patients with non-insulin-dependent diabetes mellitus previously well controlled with insulin. Endocr Pract 3:344-348
55. Ryysy L, Yki-Jarvinen H (2001) Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care 24:549-554
56. Stenman S, Melander A, Groop PH, Groop LC (1993) What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118:169-172